Drug Database
IO

ior-t3 (IORt3)

✓ Approved

Center of Molecular Immunology · CD3E · Monoclonal Antibodies

What is ior-t3?

ior-t3 is a monoclonal antibodies developed by Center of Molecular Immunology. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesIORt3
CompanyCenter of Molecular Immunology
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetCD3E
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Center of Molecular Immunology

Mechanism of Action

Molecular Targets

ior-t3 acts on 1 molecular target:

CD3ECD3 epsilon subunit of T-cell receptor complex (TCRE, CD3epsilon)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ior-t3 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersSolid organ transplant rejection✓ Approved

Related Research Articles

PubMedFrontiers in oncology2026-10-22

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study.

Wang Suping S, Wang Xiuyan X, Jiang Ni N, Hu Yongpei Y et al.

The aims of this study were to explore the longitudinal trajectories of core symptoms in survivors with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) and to analyze their associations with health-related quality of life (HRQoL) and unmet supportive care needs. This longitudinal study enrolled 271 HCC survivors undergoing TACE in China. Patient-reported outcomes were assessed at three time points-24 h (T1), 7 days (T2), and 1 month (T3) post-TACE-using four validated instruments: the MD Anderson Symptom Inventory-Chinese Version (MDASI-C), the Tumor Symptom Measure for Primary Liver Cancer (TSM-PLC), the Quality of Life Instrument for Liver Cancer (QOL-LC V2.0), and the Short Form of Survivors' Unmet Needs Scale (SF-SUNS). Exploratory factor analysis was conducted to extract discrete symptom clusters, and network analysis was used to calculate strength centrality (rs)-an index quantifying the sum of absolute edge weights connecting each symptom to all others-to identify core symptoms. Five symptom clusters were identified at T1: Fatigue-Cognitive, Post-embolization, Somatic, Emotional, and Hepatobiliary-Specific. The Post-embolization cluster was present only at T1, whereas the remaining four clusters persisted at T2 and T3. However, the core symptom shifted over time: nausea at T1 (rs = 1.154), lack of appetite at T2 (rs = 1.229), and sadness at T3 (rs = 1.107). HRQoL was lowest at T1, improved at T2, and declined at T3, with all pairwise comparisons significant (all p < 0.001). Unmet needs were highest at T3, with all time-point differences significant (all p < 0.001). The largest gaps were observed in information provision, care continuity, and emotional support. Greater symptom severity was significantly associated with poorer HRQoL at all time points (all p < 0.01). During the first month post-TACE, the sequence of core symptoms transitioned from nausea to lack of appetite and then to sadness, suggesting time-specific supportive care strategies-including antiemetic prophylaxis, nutritional support, and psychosocial care. Routine assessment of unmet needs may help reduce symptom burden and optimize long-term HRQoL for these survivors.

PMID 42903105
Read full article →
PubMedKidney research and clinical practice2026-10-22

Association of alkaline phosphatase with mortality in patients on peritoneal dialysis.

Kim Jae Young JY, Chang Tae Ik TI, Kang Ea Wha EW

Patients with end-stage kidney disease (ESKD) undergoing peritoneal dialysis (PD) experience high mortality rates, necessitating the establishment of reliable prognostic markers. Although serum alkaline phosphatase (ALP) is routinely measured while assessing chronic kidney disease-mineral and bone disorder, its clinical relevance for mortality risk in patients undergoing PD has not been fully established. Using multivariable Cox proportional hazards models, this retrospective cohort study examined the association between baseline ALP levels and risk of all-cause and cardiovascular mortality in 1,108 patients with ESKD who newly initiated PD between 2000 and 2020. The median ALP level of the overall cohort was 76.0 IU/L (interquartile range, 60.0-95.3 IU/L). The mean age of the patients was 60.6 years (standard deviation [SD], 14.4 years), and 55.8% were male. During a median follow-up of 4.0 years, a 1-SD increase in ALP level was significantly associated with a 23% and 64% higher risk of all-cause mortality (95% confidence interval [CI], 1.09-1.38) and cardiovascular mortality (95% CI, 1.21-2.24), respectively. The patients were stratified into tertiles (T1-T3) based on ALP level. Compared with the T1 group, the adjusted hazard ratios for all-cause mortality were 1.11 (95% CI, 0.84-1.48) in T2 and 1.39 (95% CI, 1.05-1.85) in T3. The relationship between elevated ALP and higher risk of all-cause mortality was consistent when ALP was treated as a time-dependent variable. Elevated ALP levels were associated with increased risk of all-cause and cardiovascular mortality in patients undergoing PD.

PMID 42902883
Read full article →
PubMedBMC musculoskeletal disorders2026-10-21

Effectiveness of three remote tele-prehabilitation strategies in patients awaiting lower limb arthroplasty: a three-arm randomized controlled trial.

Patanè Pamela P, Pellino Vittoria Carnevale VC, Manzoni Federica F, Caldarella Emanuele E et al.

Lower limb arthroplasty (LLA), including total hip and total knee arthroplasty (THA and TKA), ranks among the most frequently performed elective orthopedic procedures worldwide. Patients on surgical waiting lists commonly present with reduced muscle strength, impaired mobility, and diminished cardiorespiratory fitness, all associated with delayed postoperative recovery. Prehabilitation aims to optimize preoperative functional capacity; however, adherence to center-based approaches remains suboptimal. Telerehabilitation offers a viable alternative, yet evidence on tele-prehabilitation for LLA candidates and comparisons between remote modalities remain scarce. This randomized clinical trial evaluated three tele-prehabilitation strategies on preoperative functional outcomes in patients awaiting LLA. Sixty patients scheduled for elective TKA or THA were randomly allocated 1:1:1 to one of three four-week programmes: neuromuscular electrical stimulation (NMES), physiotherapist-supervised online exercise (SV), or unsupervised brochure-guided home exercise (BR), each comprising three 30-min sessions per week. No usual-care or non-intervention control group was included, as all three study arms received an active tele-prehabilitation intervention. Assessments were conducted at baseline (T0) and post-prehabilitation (T1) remotely via videoconference, and in person on postoperative day 4 (T2) and day 10 (T3). The primary outcomes were the 30-Second Chair Stand Test (30-CST), the Timed Up and Go test (TUG), and the Oxford Hip/Knee Score (OHS/OKS), assessed preoperatively at T0 and post-prehabilitation at T1. The secondary outcomes were the Six-Minute Walk Test (6MWT) and length of hospital stay (LOS), assessed postoperatively at day 4 (T2) and day 10 (T3). The a priori sample size calculation was based on the 6MWT as a clinically relevant and responsive indicator of early postoperative functional recovery following arthroplasty; the rationale for this choice and its implications for interpreting preoperative functional endpoints are discussed in the Limitations section. All three groups demonstrated significant within-group improvements across most functional outcomes (p < 0.001). NMES achieved significantly greater reductions in TUG compared with both SV and BR, and superior gains in 6MWT and Oxford score relative to SV. No significant differences were observed between NMES and BR for 30CST, 6MWT, or Oxford score. Notably, BR demonstrated significantly greater improvement in 6MWT than SV, despite the absence of real-time supervision. Tele-prehabilitation is feasible, well tolerated, and associated with meaningful functional improvements across all modalities. However, as all three groups received an active intervention, these findings reflect relative comparisons between remote modalities rather than efficacy versus standard care or no intervention. NMES demonstrated a more favorable comparative profile for selected mobility-related outcomes, particularly TUG, whereas no significant between-group differences were found for the 30-s chair stand test, particularly for mobility-related outcomes, while brochure-guided exercise proved largely equivalent to NMES on most endpoints. These findings support remote NMES and structured self-directed exercise as accessible, scalable alternatives to supervised prehabilitation for patients awaiting LLA. ClinicalTrials.gov Identifier: NCT06363643; Registered 12 April 2024. https://clinicaltrials.gov/study/NCT06363643.

PMID 42902309
Read full article →
PubMedJournal of animal science and technology2026-10-20

Identification of the optimal monosodium glutamate-condensed molasses solubles inclusion level replacing molasses in growing-finishing pigs.

Yang Jinmo J, Park Sooyoung S, Lee Jihwan J, Song Minho M et al.

This study aimed to evaluate the effects of replacing molasses with monosodium glutamate (MSG)-condensed molasses solubles (CMS) in growing-finishing pig diets and determine the optimal replacement ratio. Experiment 1, a total of 100 crossbred growing-finishing pigs ([Landrace × Yorkshire] × Duroc) (9 weeks of age; initial body weight 23.17 ± 3.51 kg) were randomly assigned to five dietary treatments for 14 weeks, with four replicates per treatment and five pigs per replicate. The treatments consisted of: (1) PC (basal diet with 2% molasses), (2) NC (basal diet), (3) T1 (basal diet with 1.5% molasses + 0.5% MSG-CMS), (4) T2 (basal diet with 1% molasses + 1% MSG-CMS), and (5) T3 (basal diet with 2% MSG-CMS). Growth performance, nutrient digestibility, blood profiles, fecal microbiota, and economic efficiency were assessed. Average daily gain in the T1 was higher (p < 0.05) than that in the T3. The average daily feed intake in the T3 was lower (p < 0.05) than that in the PC and T1 groups. In contrast, T1 and T2 had higher (p < 0.05) average daily feed intake than the NC. Economically, the T1 showed higher total weight gain and lower (p < 0.05) feed cost per kg gain than the PC and T3 during the growing phase. Experiment 2, a total of 5 crossbred growing-finishing pigs (11 weeks of age; initial body weight 36.84 ± 0.51 kg) were used in a 5-week metabolism trial based on a 5 × 5 Latin square design to investigate the effects of MSG-CMS on nutrient digestibility and nitrogen retention. The T1 had higher (p < 0.05) gross energy digestibility than the T3. Fecal nitrogen excretion was lower (p < 0.05) in the T1 than in the T2, while the T2 had higher (p < 0.05) total nitrogen excretion than the NC. In conclusion, molasses can be replaced with MSG-CMS without negative effects, with 25% replacement being the most effective for improving growth performance, nutrient digestibility, and economic efficiency in growing-finishing pigs.

PMID 42898895
Read full article →
PubMedCanadian journal of pain = Revue canadienne de la douleur2026-10-20

Impacts of the iCanCope Digital Pain Self-Management Program Among Adolescents and Young Adults With Chronic Pain: A Randomized Controlled Trial.

Lalloo Chitra C, Nishat Fareha F, Palermo Tonya T, Montgomery Lori L et al.

iCanCope™ (ICC) is a digital self-management program for 15-25 year olds with chronic pain. This study evaluated program satisfaction and efficacy through a two arm randomized controlled trial in Canadian tertiary care pain clinics. Participants were randomized to receive either ICC (app and website with symptom tracking and trending, pain education, goal setting, library, community forum) or an identically branded active control program with limited features. Outcomes were assessed at baseline, postprogram (2 months; T2), and follow-up (6 months; T3). Satisfaction was assessed using the Acceptability eScale and qualitatively with a subset of intervention participants. Linear mixed effects models characterized treatment effects on primary (pain interference) and secondary outcomes. Of 302 enrolled participants, 297 were analyzed (mean age = 17.1 ± 2.4, 83% female). Outcome completion rates were 89% at T2 and 71% at T3. Program acceptability was high in both the intervention (33.9 ± 7.0) and control group (32.7 ± 6.8). Most participants exhibited moderate to high engagement with daily checkins (intervention: 79%, active control: 80%). No significant treatment effects were found. However, improvements across time in pain interference at T2 (β = -0.58, p < .001) and T3 (β = -0.64, p = .0016) and improvements in knowledge about managing pain at T2 (β = -0.54, p < .0001) and T3 (β = -1.04, p < .0001) were found for both groups. Most (15/16) interviewees reported that ICC enhanced their confidence and/or ability to engage in pain self-management. Digitally mediated symptom tracking and trending and pain education is engaging and beneficial for 15-25 year olds with chronic pain. Use of an active-control may have diminished the ability to detect treatment-group effects. ICC has been translated to French-Canadian and publicly released as a free self-management tool. Trial Registration: ClinicalTrials.gov, NCT02601755.

PMID 42899170
Read full article →
PubMedArthritis care & research2026-10-20

The association of gout flare resolution with physical activity and sleep: a prospective remote-monitoring study.

Stewart Sarah S, Girven Boston B, Clarke Mia M, Zeng Irene I et al.

This study aimed to determine whether gout flare resolution is associated with physical activity and sleep. These findings were intended to inform the future development of a definition for flare resolution. Data from 81 participants with gout who experienced >1 flare during a 6-month prospective observational study were included. Daily activity (step count) and sleep (total sleep time and deep sleep percentage) were collected remotely using wrist-worn trackers. Daily flare occurrence was captured using smartphone diaries. Activity/sleep outcomes during each flare episode were compared to those during three resolution timeframes: T1: the first day following the flare; T2: the consecutive window immediately following the flare and equal in length to the flare; and T3: the consecutive window equal in length to the flare and immediately following a washout window (equal in length to the flare). Adjusted differences in medians between flare and resolution timeframes were estimated using linear quantile mixed models. Daily step count was lower during flares compared with all resolution timeframes (all P<0.033). T3 provided the best overall model fit, suggesting that resolution is most clearly distinguished from the flare when using this timeframe. No significant differences between flare and resolution were observed for the sleep outcomes for any resolution timeframe. Physical activity improves soon after flare cessation, with the clearest distinction between flare and resolution observed over a longer post-flare recovery period, whereas sleep metrics do not differentiate flare from resolution states. These findings support physical activity as a useful objective domain for gout flare resolution.

PMID 42901866
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ior-t3